[Receptor mechanism of the neuroprotective effect of GABAergic agents].
Kulinskiĭ
V I
VI
Mikhel'son
G V
GV
D000818:Animals; D001418:Baclofen / Q000494:pharmacology; D002545:Brain Ischemia / Q000517:prevention & control; D005260:Female; D018755:GABA Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D018756:GABA Antagonists / Q000494:pharmacology; D007276:Injections, Intraventricular; D007279:Injections, Subcutaneous; D007540:Isonipecotic Acids / Q000494:pharmacology; D007555:Isoxazoles / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D009118:Muscimol / Q000494:pharmacology; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D011963:Receptors, GABA-A / Q000187:drug effects*; D018080:Receptors, GABA-B / Q000187:drug effects*
D018755:GABA Agonists; D018756:GABA Antagonists; D007540:Isonipecotic Acids; D007555:Isoxazoles; D018696:Neuroprotective Agents; D011963:Receptors, GABA-A; D018080:Receptors, GABA-B; D009118:Muscimol; D001418:Baclofen; C015542:gaboxadol